SIGY (Sigyn Therapeutics) Moat Score: 2/10 (As of Jul. 05, 2026)


What is Sigyn Therapeutics Moat Score?

Sigyn Therapeutics SIGY +22.62% Moat Score is 2 as of Jul. 05, 2026. The stock has 3 warning signs investors should review. Among 1,395 Biotechnology companies, Sigyn Therapeutics ranks better than 58.28% on this metric.

Sigyn Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Sigyn Therapeutics has No Moat: Sigyn Therapeutics Inc lacks significant market leadership, network effects, or strong intellectual property. The company does not exhibit durable cost advantages or significant regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sigyn Therapeutics might have No Moat - Very weak/transient advantages.

Sigyn Therapeutics  (OTCPK:SIGY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sigyn Therapeutics Moat Score Related Terms

SIGY vs RGBP, ENDV, VRTX: Moat Score Comparison

For the Biotechnology subindustry, Sigyn Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sigyn Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Sigyn Therapeutics (SIGY) has a Moat Score of 2 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sigyn Therapeutics ranks #582 out of 1395 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Sigyn Therapeutics' Moat Score too high?
Sigyn Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Sigyn Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Sigyn Therapeutics ranks #582 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint.
How does Sigyn Therapeutics' Moat Score compare to RGBP and ENDV?
According to the Biotechnology industry distribution chart, Sigyn Therapeutics ranks #582 out of 1395 companies for Moat Score. This puts Sigyn Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Sigyn Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sigyn Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigyn Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Moat Score is 2 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.